Irritable bowel syndrome other imaging findings

Irritable bowel syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Irritable bowel syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Monitoring
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Case Studies
Case #1
Irritable bowel syndrome other imaging findings On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Irritable bowel syndrome other imaging findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Irritable bowel syndrome other imaging findings
CDC on Irritable bowel syndrome other imaging findings
Irritable bowel syndrome other imaging findings in the news
Blogs on Irritable bowel syndrome other imaging findings
Directions to Hospitals Treating Irritable bowel syndrome
Risk calculators and risk factors for Irritable bowel syndrome other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There are no other imaging findings associated with [disease name].

OR

[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

Other Imaging Findings

• IBS patients with diarrhea sometimes have bile acid diarrhea on 23-seleno-25-homotaurocholic acid (75SeHCAT) testing.
• The 75SeHCAT test measures the whole-body retention of 75Se-homocholyltaurine, a bile acid radiolabeled with the gamma-emitting isotope selenium-75.
• Retention of the isotope is measured by gamma-camera scanning performed a week after administration. . 
• There are no other imaging findings associated with [disease name].

• [Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include:
  • [Finding 1]
  • [Finding 2]
  • [Finding 3]